National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, and Department of Infectious Diseases, Imperial College London, London, UK.
National Institute of Health Research Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance, and Department of Infectious Diseases, Imperial College London, London, UK.
Lancet. 2016 Jan 9;387(10014):176-87. doi: 10.1016/S0140-6736(15)00473-0. Epub 2015 Nov 18.
To combat the threat to human health and biosecurity from antimicrobial resistance, an understanding of its mechanisms and drivers is needed. Emergence of antimicrobial resistance in microorganisms is a natural phenomenon, yet antimicrobial resistance selection has been driven by antimicrobial exposure in health care, agriculture, and the environment. Onward transmission is affected by standards of infection control, sanitation, access to clean water, access to assured quality antimicrobials and diagnostics, travel, and migration. Strategies to reduce antimicrobial resistance by removing antimicrobial selective pressure alone rely upon resistance imparting a fitness cost, an effect not always apparent. Minimising resistance should therefore be considered comprehensively, by resistance mechanism, microorganism, antimicrobial drug, host, and context; parallel to new drug discovery, broad ranging, multidisciplinary research is needed across these five levels, interlinked across the health-care, agriculture, and environment sectors. Intelligent, integrated approaches, mindful of potential unintended results, are needed to ensure sustained, worldwide access to effective antimicrobials.
为了应对抗生素耐药性对人类健康和生物安全构成的威胁,我们需要了解其机制和驱动因素。微生物中抗生素耐药性的出现是一种自然现象,但在医疗保健、农业和环境中抗生素的暴露推动了抗生素耐药性的选择。传播的继续受到感染控制、卫生、清洁水的获取、有保证的质量抗生素和诊断的获取、旅行和移民的标准的影响。仅通过消除抗生素选择压力来减少抗生素耐药性的策略依赖于耐药性赋予的适应性成本,而这种效果并不总是明显的。因此,应全面考虑最小化耐药性,包括耐药机制、微生物、抗生素药物、宿主和背景;与新药发现并行,需要在这五个层面上开展广泛的多学科研究,在医疗保健、农业和环境部门之间相互关联。需要明智、综合的方法,注意潜在的意外结果,以确保在全球范围内持续获得有效的抗生素。